PRX IV Double Nickase Plasmid (h): sc-402821-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PRX IV Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PRX IV Double Nickase Plasmid (h) and PRX IV Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PRDX4. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PRX IV Antibody (F-2): sc-376668
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRX IV Double Nickase Plasmid (h) | sc-402821-NIC | 20 µg | $410.00 | |||
PRX IV Double Nickase Plasmid (h2) | sc-402821-NIC-2 | 20 µg | $410.00 |
Human PRDX4 encodes peroxiredoxin IV (PRX IV), an endoplasmic reticulum and secretory pathway thiol-dependent peroxidase that reduces hydrogen peroxide and lipid peroxides to maintain redox homeostasis. By coupling peroxide detoxification to disulfide bond formation, PRX IV supports oxidative protein folding, ER proteostasis, and attenuation of unfolded protein response signaling under oxidative stress. PRDX4 activity intersects with redox-regulated pathways controlling secretion, inflammation, and cell survival, and altered expression or oxidation state has been associated with oxidative stress phenotypes reported across cancer biology, metabolic dysfunction, and cardiovascular and inflammatory contexts. As a secreted/ER redox enzyme, PRX IV is frequently studied for its impact on extracellular and luminal ROS buffering and the downstream modulation of stress-adaptive transcriptional programs.
PRX IV Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PRDX4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PRDX4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PRDX4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PRDX4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.